CN1634302A - 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 - Google Patents
治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 Download PDFInfo
- Publication number
- CN1634302A CN1634302A CNA2004100523570A CN200410052357A CN1634302A CN 1634302 A CN1634302 A CN 1634302A CN A2004100523570 A CNA2004100523570 A CN A2004100523570A CN 200410052357 A CN200410052357 A CN 200410052357A CN 1634302 A CN1634302 A CN 1634302A
- Authority
- CN
- China
- Prior art keywords
- gout
- medicine
- group
- capsule
- hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 121
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 15
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title description 27
- 238000011282 treatment Methods 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000007908 dry granulation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- -1 dry granulation Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 241000201320 Ligustrum japonicum Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 77
- 241000700159 Rattus Species 0.000 description 47
- 239000008280 blood Substances 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 30
- 230000000694 effects Effects 0.000 description 24
- 230000037396 body weight Effects 0.000 description 22
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 21
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 18
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 18
- 229940116269 uric acid Drugs 0.000 description 18
- 230000006870 function Effects 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 206010018634 Gouty Arthritis Diseases 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 229960000905 indomethacin Drugs 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 6
- 238000011047 acute toxicity test Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229940096998 ursolic acid Drugs 0.000 description 4
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000037039 Monarthritis Diseases 0.000 description 2
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 2
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000002579 anti-swelling effect Effects 0.000 description 2
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 2
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229930187479 gypenoside Natural products 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061430 Arthritis allergic Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- JLPDBLFIVFSOCC-UHFFFAOYSA-N Oleandrin Natural products O1C(C)C(O)C(OC)CC1OC1CC(CCC2C3(CC(C(C3(C)CCC32)C=2COC(=O)C=2)OC(C)=O)O)C3(C)CC1 JLPDBLFIVFSOCC-UHFFFAOYSA-N 0.000 description 1
- VUGRLRAUZWGZJP-UHFFFAOYSA-N Plantaginin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-YTECAPLWSA-N methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C(C(C/1=C\C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-YTECAPLWSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 1
- 229950010050 oleandrin Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VUGRLRAUZWGZJP-IAAKTDFRSA-N plantaginin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 VUGRLRAUZWGZJP-IAAKTDFRSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
1h | 2h | 3h | 4h | 5h | 6h | |
生理盐水 | 0.40±0.14 | 0.56±0.19 | 0.61±0.12 | 0.64±0.14 | 0.51±0.18 | 0.47±0.14 |
阳性药 | 0.36±0.06 | 0.27±0.18** | 0.18±0.17*** | 0.15±0.10*** | 0.12±0.09*** | 0.09±0.06*** |
痛风胶囊-大 | 0.10±0.10*** | 0.25±0.15*** | 0.32±0.15*** | 0.20±0.13*** | 0.27±0.17** | 0.24±0.16** |
痛风胶囊-中 | 0.32±0.17 | 0.24±0.13*** | 0.22±0.15*** | 0.20±0.18*** | 0.29±0.09** | 0.19±0.12*** |
痛风胶囊-小 | 0.11±0.11*** | 0.21±0.10*** | 0.21±0.09*** | 0.16±0.11*** | 0.26±0.13** | 0.22±0.14*** |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100523570A CN1290529C (zh) | 2004-11-24 | 2004-11-24 | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100523570A CN1290529C (zh) | 2004-11-24 | 2004-11-24 | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634302A true CN1634302A (zh) | 2005-07-06 |
CN1290529C CN1290529C (zh) | 2006-12-20 |
Family
ID=34846129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100523570A Active CN1290529C (zh) | 2004-11-24 | 2004-11-24 | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1290529C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926855A (zh) * | 2010-08-25 | 2010-12-29 | 肖富洲 | 降低痛风患者尿酸的药茶 |
CN102908436A (zh) * | 2012-11-12 | 2013-02-06 | 易春莲 | 一种对痛风有疗效的颗粒型固体饮料及其制备方法 |
CN104546987A (zh) * | 2013-10-16 | 2015-04-29 | 浙江中医药大学 | 绞股蓝总皂苷在防治高尿酸血症中的应用 |
CN104644768A (zh) * | 2015-02-07 | 2015-05-27 | 广州暨南生物医药研究开发基地有限公司 | 一种中药组合物在制备治疗肾脏疾病药物中的用途 |
CN107898947A (zh) * | 2017-12-20 | 2018-04-13 | 何宝兰 | 一种治疗痛风、高尿酸血症的草本组合物及其制备方法和应用 |
CN113679742A (zh) * | 2021-08-30 | 2021-11-23 | 神农架林区蜜蜂天堂食品有限公司 | 一种蜂房醇提物的制备方法及其应用 |
-
2004
- 2004-11-24 CN CNB2004100523570A patent/CN1290529C/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926855A (zh) * | 2010-08-25 | 2010-12-29 | 肖富洲 | 降低痛风患者尿酸的药茶 |
CN102908436A (zh) * | 2012-11-12 | 2013-02-06 | 易春莲 | 一种对痛风有疗效的颗粒型固体饮料及其制备方法 |
CN102908436B (zh) * | 2012-11-12 | 2014-03-26 | 易春莲 | 一种对痛风有疗效的颗粒型固体饮料及其制备方法 |
CN104546987A (zh) * | 2013-10-16 | 2015-04-29 | 浙江中医药大学 | 绞股蓝总皂苷在防治高尿酸血症中的应用 |
CN104644768A (zh) * | 2015-02-07 | 2015-05-27 | 广州暨南生物医药研究开发基地有限公司 | 一种中药组合物在制备治疗肾脏疾病药物中的用途 |
CN107898947A (zh) * | 2017-12-20 | 2018-04-13 | 何宝兰 | 一种治疗痛风、高尿酸血症的草本组合物及其制备方法和应用 |
CN113679742A (zh) * | 2021-08-30 | 2021-11-23 | 神农架林区蜜蜂天堂食品有限公司 | 一种蜂房醇提物的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1290529C (zh) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1309399C (zh) | 复方双黄连制剂及制备方法 | |
CN100337662C (zh) | 一种治疗高血脂症的药物组合物及其制备方法 | |
CN1180792C (zh) | 防治白细胞减少症的中药制剂及制备工艺 | |
CN1762967A (zh) | 甘草次酸衍生物、制备方法及其用途 | |
CN1698713A (zh) | 一种治疗风湿痹痛的复方风湿宁组合物及制剂 | |
CN1709376A (zh) | 治疗气滞型胃脘痛的中药复方制剂及其制备方法 | |
CN1132615C (zh) | 具有调节血糖功效的保健品及其制备方法 | |
CN1559590A (zh) | 一种治疗产后缺乳的颗粒剂及其制备方法 | |
CN1290529C (zh) | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 | |
CN1557842A (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
CN1191082C (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1785307A (zh) | 治疗乳腺囊性增生及乳腺炎中药及其薄膜衣片的制备方法 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1562337A (zh) | 治疗肾阳虚的中药及其制备方法 | |
CN1548138A (zh) | 一种治疗虚损病的中药组合物及其质量控制方法 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1319588C (zh) | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 | |
CN1879706A (zh) | 双黄连分散片及其制备方法 | |
CN101057952A (zh) | 一种治疗痛经的药物组合物及其制备方法和应用 | |
CN1194743C (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法和质量控制方法 | |
CN1730083A (zh) | 元合片及其制备方法 | |
CN1593482A (zh) | 一种治疗中老年记忆力减退的药物及其制备方法 | |
CN1562144A (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN1323688C (zh) | 一种治疗前列腺疾病的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU LANYUN MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG JING Effective date: 20100831 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510632 ROOM 601, NO.15, HUAJING ROAD, TIANHE DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 D909, INTERNATIONAL BUSINESS INCUBATOR ZONE D, NO.3, JUQUAN ROAD, SCIENCE CITY OF HIGH-TECH INDUSTRIAL DEVELOPMENT AREA, GUANGZHOU |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100831 Address after: 510663 high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee after: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. Address before: 510632 Guangdong city of Guangzhou province Tianhe District Hua Jing Lu No. 15 Room 601 Patentee before: Zhang Jing |
|
DD01 | Delivery of document by public notice |
Addressee: Zhang Jing Document name: Notification of Passing Examination on Formalities |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 510663 Guangdong city of Guangzhou province high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator B District 301 Patentee after: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. Address before: Guangzhou hi tech Industrial Development Zone, Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee before: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230627 Address after: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee after: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. Address before: 510663 No.301, zone B, Guangzhou International Business Incubator, No.3, Juquan Road, Science City, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Building D, 2nd Floor, No. 1168 Huanli Road, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen City, Guangdong Province, 518107 Patentee after: Hongtai (Shenzhen) Pharmaceutical Technology Co.,Ltd. Address before: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee before: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. |